144 related articles for article (PubMed ID: 36680928)
21. SPAG5 promotes osteosarcoma metastasis via activation of FOXM1/MMP2 axis.
Li Z; Li H; Chen J; Luo H; Zeng J; Yao Y; Duan M
Int J Biochem Cell Biol; 2020 Sep; 126():105797. PubMed ID: 32668328
[TBL] [Abstract][Full Text] [Related]
22. Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell.
Ba G; Hua Z; Xu N; Zhang S; Liu Z; Thiele CJ; Li Z
Cell Cycle; 2020 Jun; 19(12):1530-1544. PubMed ID: 32401122
[TBL] [Abstract][Full Text] [Related]
23. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
24. Bruceine D inhibits tumor growth and stem cell-like traits of osteosarcoma through inhibition of STAT3 signaling pathway.
Wang S; Hu H; Zhong B; Shi D; Qing X; Cheng C; Deng X; Zhang Z; Shao Z
Cancer Med; 2019 Dec; 8(17):7345-7358. PubMed ID: 31631559
[TBL] [Abstract][Full Text] [Related]
25. MUC1-C drives stemness in progression of colitis to colorectal cancer.
Li W; Zhang N; Jin C; Long MD; Rajabi H; Yasumizu Y; Fushimi A; Yamashita N; Hagiwara M; Zheng R; Wang J; Kui L; Singh H; Kharbanda S; Hu Q; Liu S; Kufe D
JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32427590
[TBL] [Abstract][Full Text] [Related]
26. HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
La Noce M; Paino F; Mele L; Papaccio G; Regad T; Lombardi A; Papaccio F; Desiderio V; Tirino V
J Exp Clin Cancer Res; 2018 Dec; 37(1):296. PubMed ID: 30509303
[TBL] [Abstract][Full Text] [Related]
27. MUC1: a multifaceted oncoprotein with a key role in cancer progression.
Nath S; Mukherjee P
Trends Mol Med; 2014 Jun; 20(6):332-42. PubMed ID: 24667139
[TBL] [Abstract][Full Text] [Related]
28. IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells.
Wang M; Wang L; Ren T; Xu L; Wen Z
Cancer Biol Ther; 2013 Feb; 14(2):155-63. PubMed ID: 23192273
[TBL] [Abstract][Full Text] [Related]
29. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells.
Tang QL; Zhao ZQ; Li JC; Liang Y; Yin JQ; Zou CY; Xie XB; Zeng YX; Shen JN; Kang T; Wang J
Cancer Lett; 2011 Dec; 311(1):113-21. PubMed ID: 21835542
[TBL] [Abstract][Full Text] [Related]
30. Unveiling the protein signature of the human osteosarcoma 3AB-OS cancer stem cell line.
Imperlini E; Corbo C
Biochem Biophys Res Commun; 2023 Oct; 676():36-41. PubMed ID: 37481941
[TBL] [Abstract][Full Text] [Related]
31. Cancer stem cells in osteosarcoma.
Brown HK; Tellez-Gabriel M; Heymann D
Cancer Lett; 2017 Feb; 386():189-195. PubMed ID: 27894960
[TBL] [Abstract][Full Text] [Related]
32. Proteomics of osteosarcoma.
Bernardini G; Laschi M; Geminiani M; Santucci A
Expert Rev Proteomics; 2014 Jun; 11(3):331-43. PubMed ID: 24654989
[TBL] [Abstract][Full Text] [Related]
33. Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.
Hata T; Rajabi H; Yamamoto M; Jin C; Ahmad R; Zhang Y; Kui L; Li W; Yasumizu Y; Hong D; Miyo M; Hiraki M; Maeda T; Suzuki Y; Takahashi H; Samur M; Kufe D
Mol Cancer Ther; 2019 Oct; 18(10):1744-1754. PubMed ID: 31308076
[TBL] [Abstract][Full Text] [Related]
34. Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival.
Guo L; Yan T; Guo W; Niu J; Wang W; Ren T; Huang Y; Xu J; Wang B
Front Immunol; 2022; 13():986785. PubMed ID: 36059448
[TBL] [Abstract][Full Text] [Related]
35. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
[TBL] [Abstract][Full Text] [Related]
36. [Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells].
Liu PY; Zhang WB; Wang J; Shen YH; Wei YY
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):175-80. PubMed ID: 23879996
[TBL] [Abstract][Full Text] [Related]
37. The multifaceted role of MUC1 in tumor therapy resistance.
Jin W; Zhang M; Dong C; Huang L; Luo Q
Clin Exp Med; 2023 Sep; 23(5):1441-1474. PubMed ID: 36564679
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells.
Paiva-Oliveira DI; Martins-Neves SR; Abrunhosa AJ; Fontes-Ribeiro C; Gomes CMF
Cancer Chemother Pharmacol; 2018 Jan; 81(1):49-63. PubMed ID: 29086064
[TBL] [Abstract][Full Text] [Related]
39. The Na+/K+ ATPase Inhibitor Ouabain Attenuates Stemness and Chemoresistance of Osteosarcoma Cells.
Guo W; Wei B; Cheng T; Xu X; Ruan F; Xiang M
Med Sci Monit; 2019 Dec; 25():9426-9434. PubMed ID: 31822650
[TBL] [Abstract][Full Text] [Related]
40. ELK1-induced upregulation of long non-coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2.
Su X; Teng J; Jin G; Li J; Zhao Z; Cao X; Guo Y; Guo M; Li X; Wu J; Wang C; Guo Z; Guo Q
Biomed Pharmacother; 2019 Jan; 109():788-797. PubMed ID: 30551532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
